Sanofi notches another Pompe win with FDA blessing for enzyme replacement therapy Nexviazyme

The FDA cleared Sanofi’s Nexviazyme, also known as avalglucosidase alfa-ngpt, to treat patients ages one and older with late-onset Pompe disease, which damages the muscles over time, the company said Friday. It marks the FDA’s second approved drug for the rare genetic disease, the first of which also belongs to Sanofi.